Onkologie und Ökonomie – wie frei sind wir wirklich in der Behandlung von Patient*innen?

Wörmann, Bernhard; Hecken, Josef; Steutel, Han; Tamm, Ingo; Ullmann, Andrew J.; Kappert-Gonther, Kirsten; Einsele, Hermann; Siess, M.; Wylegalla, Christian

doi:10.1159/000517496

Oncol Res Treat

2021

DOI: 10.1159/000517496

|View full text |Cite

Onkologie und Ökonomie – wie frei sind wir wirklich in der Behandlung von Patient*innen?

Bernhard Wörmann

Josef Hecken

Han Steutel³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 13 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit

Kleining,

Laufenberg,

Thrun

et al. 2023

HEPL

View full text Add to dashboard Cite

Introduction Since 2011, the prices for all new drugs in Germany are negotiated based on a benefit assessment. The purpose of this study was to analyze the price regulation of drugs with unproven additional benefit. Methods Benefit assessment procedures from 2011 to 2020 were reviewed and selected through AMNOG Monitor and Lauer Taxe. Negotiated annual therapy costs, the annual costs of the most cost-efficient appropriate comparative therapy (ACT) and the potential budget impact for 33 included procedures were calculated. Results 55% of the included drugs achieved a negotiated price higher than the most cost-efficient ACT, 3% were identified as equal and 42% showed lower negotiated prices. The potential savings exceeded expenditures by around EUR 523.5 m. After price flexibility was adopted by the legislator in 2017, the overall potential savings still outweighed the expenditures by around EUR 62 m. Conclusions Our analysis shows that making price negotiations more flexible by law does not undermine the fundamental aim of the AMNOG, which is to avoid additional expenditure without increased patient benefit. The regulation can thus fulfill the objective provided by the legislature of keeping drugs without proven additional benefits in the German healthcare system.

show abstract

Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit

Kleining,

Laufenberg,

Thrun

et al. 2023

HEPL

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Onkologie und Ökonomie – wie frei sind wir wirklich in der Behandlung von Patient*innen?

Cited by 1 publication

References 13 publications

Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit

Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit

Contact Info

Product

Resources

About